Pregnancy with chronic myeloid leukemia: case report and literature review

Authors

  • Tanzeem Sabina Chowdhury Department of Obstetrics and Gynecology, BIRDEM General Hospital and Ibrahim Medical College, 122, Kazi Nazrul Islam Avenue, Shahbag, Dhaka, Bangladesh
  • Israt Jerin Department of Obstetrics and Gynecology, BIRDEM General Hospital and Ibrahim Medical College, 122, Kazi Nazrul Islam Avenue, Shahbag, Dhaka, Bangladesh
  • T. A. Chowdhury Department of Obstetrics and Gynecology, BIRDEM General Hospital and Ibrahim Medical College, 122, Kazi Nazrul Islam Avenue, Shahbag, Dhaka, Bangladesh

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20195369

Keywords:

Chronic myeloid leukemia, Hydroxyurea, Interferon- α, Leukemia, Teratogenicity, Tyrosine kinase inhibitor

Abstract

Chronic myeloid leukemia (CML) is a rare condition during reproductive age. Still, women may present with pre-existing or newly diagnosed CML during pregnancy. The management of chronic myeloid leukemia during pregnancy requires balancing the well-being of the mother with that of fetus. Tyrosine Kinase inhibitors are considered the most effective drug against CML but they are still not considered safe during pregnancy and breast feeding. So, there is a need for management of CML with alternate drugs during pregnancy. Here we report a case of a 26-year-old lady who was diagnosed with chronic myelogenous leukemia (CML) at 20 weeks of gestation and had an atypical chromosome translocation t (9:22). She was managed jointly by obstetrician and haemato-oncologist for the remainder of her pregnancy and eventually she delivered a healthy baby at term.

References

Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006;94(12):1765-9.

Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al. SEER cancer statistics review, 1975-2010, National Cancer Institute, 2012.

Kantarjian HM, Talpaz M. Definition of the accelerated phase of chronic myelogenous leukemia. J Clin Oncol. 1988;6:180-2.

Lichtman M, Liesveld J. Acute myelogenous leukemia. In: Beutler E, Lichtman M, Coller B, et al., editors. Williams Hematology. 6th ed., volume 1047. New York, USA: McGraw-Hill; 2001:1074-1084.

Firas AS, Demeckova E, Mistrik M. Leukemia in pregnancy. Bratisl Lek Listy. 2008;109:364-6.

Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot R, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111:5505-8.

Apperley J. Issues of imatinib and pregnancy outcome. J Natl Compr Canc Netw. 2009;7(10):1050-8.

Shapira T, Pereg D, Lishner M. How I treat acute and chronic leukemia in pregnancy? Blood Rev. 2008;22(5):247-59.

Dowding C, Gordon M, Guo AP, Maison D, Osterholz J, Siczkowski M, et al. Potential mechanisms of action of interferon-α in CML. Leuk Lymphoma. 1993;11(Suppl 1):185-91.

Roth MS, Foon KA. Alpha interferon in the treatment of hematologic malignancies. Am J Med. 1986;81(5):871-82.

Sylvester RK, Lobell M, Teresi ME, Brundage D, Dubowy R. Excretion of hydroxyurea into milk. Cancer. 1987;60(9):2177-78.

Bhandari A, Rolen K, Shah BK. Management of chronic myelogenous leukemia in pregnancy. Anticancer Res. 2015;35:1-12.

Downloads

Published

2019-11-26

Issue

Section

Case Reports